Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

Mednet Member

Medical Oncology · Penn Medicine, University of Pennsylvania Health System

This is a difficult situation given that the literature is contradictory on this topic. Both tamoxifen and a factor V Leiden mutation independently increase risk of thromboembolic events. It is unclear whether, together, they would be additive in conferring risk of thrombosis. Dr. Cuzick wrote a ver...